Bharat Immunologicals (India) Buy Hold or Sell Recommendation

BIBCL -- India Stock  

INR 16.00  0.20  1.23%

Assuming 30 trading days horizon, and your above average risk tolerance our recommendation regarding Bharat Immunologicals Biologicals Corp Ltd is 'Hold'. Macroaxis provides Bharat Immunologicals buy hold or sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding BIBCL positions. The advice algorithm takes into account all of Bharat Immunologicals available fundamental, technical, and predictive indicators you will find on this site. The advice is provided from BIBCL buy-and-hold prospective. Check also Bharat Immunologicals Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with current analyst consensus.

Time Horizon

Risk Tolerance

Symbol
Execute Advice
Sell Bharat ImmunologicalsBuy Bharat Immunologicals
Hold

Hype Condition

Current Valuation

Odds of Distress

Economic Sensitivity

Analyst Consensus

Currently Unavailable
For the selected time horizon Bharat Immunologicals Biologicals Corp Ltd has a risk adjusted performance of 0.01, jensen alpha of 0.0, total risk alpha of 0.0, sortino ratio of 0.0 and treynor ratio of 0.0
This buy or sell advice tool can be used to cross verify current analyst consensus on Bharat Immunologicals and to analyze the company potential to grow in the current economic cycle. To make sure Bharat Immunologicals is not overpriced, please confirm all Bharat Immunologicals fundamentals including its Current Valuation, Gross Profit, Debt to Equity, as well as the relationship between Price to Book and Cash and Equivalents .

Returns Distribution Density

Mean Return0.54Value At Risk4.4
Potential Upside2.24Standard Deviation2.93
 Return Density 
      Distribution 

Bharat Immunologicals Greeks

α
Alpha over DOW
=0.00
β
Beta against DOW=0.00
σ
Overall volatility
=2.72
Ir
Information ratio =0.00

Bharat Immunologicals Volatility Alert

Bharat Immunologicals Biologicals Corp Ltd exhibits very low volatility with skewness of -1.7 and kurtosis of 5.2. However, we advise investors to further study Bharat Immunologicals Biologicals Corp Ltd technical indicators to make sure all market info is available and is reliable.
    
 Better Than Average     
    
 Worse Than Average Compare Bharat Immunologicals to competition

Bharat Immunologicals Fundamental Vs Peers

FundamentalsBharat ImmunologicalsPeer Average
Return On Asset(1.69) % (15.64) %
Profit Margin(14.86) % (5.50) %
Operating Margin(25.69) % (10.91) %
Current Valuation698.71 M152.14 B
Shares Outstanding43.18 M1.43 B
Price to Earning262.88 times40.69 times
Price to Book1.88 times14.44 times
Price to Sales2.02 times17.81 times
Revenue347.99 M9.85 B
Gross Profit48.93 M21.75 B
EBITDA(83.64 M)1.41 B
Net Income(51.73 M)517.71 M
Cash and Equivalents235.01 M3.89 B
Cash per Share5.66 times5.17 times
Total Debt14.53 M7.36 B
Debt to Equity3.80 % 0.72 %
Current Ratio1.69 times3.30 times
Book Value Per Share8.63 times13.64 times
Earnings Per Share1.20 times2.30 times
Number of Employees510.67 K
Beta-0.170.34
Market Capitalization701.68 M29.78 B
Z Score28.8708.73

Bharat Immunologicals Alerts

Trading Alerts and Improvement Suggestions
Bharat Immunologicals generates negative expected return over the last 30 days
The company reported revenue of 347.99 M. Net Loss for the year was (51.73 M) with profit before overhead, payroll, taxes, and interest of 48.93 M.
Latest headline from in.reuters.com: ICRA ratings for Indian debt instruments-Jul 27
Check also Bharat Immunologicals Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with current analyst consensus. Please also try ETF Directory module to find actively-traded exchange traded funds (etf) from around the world.